Menu
  • Call for papers – submit your abstract now

Home

Recent advances in immunotherapy for cancer have led to the licensing of new biotherapeutics for prostate cancer and melanoma. However, there is a general recognition that immunotherapy alone will not be sufficient to deliver benefit to all patients.

New combinations of immunotherapy and drug treatments have led slowly to the concept that some commonly used drugs may synergize with immunotherapy. There is increasing in vitro and in vivo evidence to support the emerging concept of chemotherapy/immunotherapy combinations for cancer.

The Cancer Vaccine Institute’s second International Symposium on Immunotherapy will be held at The Royal Society in London on the 15 – 16 May 2015.

Following the success of our first symposium held in October 2013, we have been asked to organise another such event.  This important two day symposium will explore key areas of research into synergism between immunotherapy and standard treatments in oncology and will offer an unparalleled opportunity for the international research and clinical community to come together and explore the opportunities and challenges that exist today in immunotherapy.

Key themes of the symposium will be:

  • How chemotherapy alters the immunogenicity of tumour cells
  • The effects of chemotherapy on immune regulation
  • How chemotherapy can be combined to best effect with vaccines or other immunotherapy
  • Clinical studies exploring the combinations of chemotherapy and immunotherapy

Key speakers

Paul Beckhove
Paul Beckhove
Raj Chopra
Raj Chopra
Prof Angus Dalgeish
Prof Angus Dalgeish
Leisha Emens
Leisha Emens
James Gulley
James Gulley
James Hodge
James Hodge
Dirk Jaeger
Dirk Jaeger
Dietrich Kabelitz
Dietrich Kabelitz
Rolf Kiessling TBC
Rolf Kiessling TBC
Andreas Lundqvist
Andreas Lundqvist
Delia Nelson
Delia Nelson
Dario Neri
Dario Neri
Michael Shurin
Michael Shurin
Paul Sondel
Paul Sondel